NasdaqCM - Nasdaq Real Time Price USD

Regencell Bioscience Holdings Limited (RGC)

8.03 +1.94 (+31.86%)
At close: 4:00:00 PM EDT
8.00 -0.03 (-0.37%)
After hours: 5:31:42 PM EDT
Trade RGC on Coinbase
Chart Range Bar
Loading chart for RGC
  • Previous Close 6.09
  • Open 6.02
  • Bid 6.12 x 200
  • Ask 10.07 x 200
  • Day's Range 6.00 - 8.78
  • 52 Week Range 5.80 - 69.00
  • Volume 2,539,907
  • Avg. Volume 151,181
  • Market Cap (intraday) 3.971B
  • Beta (5Y Monthly) 1.64
  • PE Ratio (TTM) --
  • EPS (TTM) -0.01
  • Earnings Date (est.) Jun 15, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

www.regencellbioscience.com

10

Full Time Employees

June 30

Fiscal Year Ends

Performance Overview

Trailing total returns as of 7/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RGC
61.76%
S&P 500 (^GSPC)
9.32%

1-Year Return

RGC
45.00%
S&P 500 (^GSPC)
20.74%

3-Year Return

RGC
1,224.39%
S&P 500 (^GSPC)
68.15%

5-Year Return

RGC
2,442.84%
S&P 500 (^GSPC)
73.23%

Statistics

View More

Valuation Measures

Annual
As of 6/30/2026
  • Market Cap

    3.03B

  • Enterprise Value

    3.02B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.48k

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -84.97%

  • Return on Equity (ttm)

    -177.66%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -7.05M

  • Diluted EPS (ttm)

    -0.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.36M

  • Total Debt/Equity (mrq)

    31.68%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

8.03 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch